UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000017791
Receipt number R000020611
Scientific Title Phase II trial of gemcitabine monotherapy in the third or further line for pretreated patients with advanced non-small cell lung cancer
Date of disclosure of the study information 2015/06/04
Last modified on 2016/08/05 13:24:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II trial of gemcitabine monotherapy in the third or further line for pretreated patients with advanced non-small cell lung cancer

Acronym

OPH-RM-LC-1502

Scientific Title

Phase II trial of gemcitabine monotherapy in the third or further line for pretreated patients with advanced non-small cell lung cancer

Scientific Title:Acronym

OPH-RM-LC-1502

Region

Japan


Condition

Condition

Non-small cell lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to evaluate an effect and safety of gemicitabine monotherapy for pre-treated patients with advanced non-small cell lung cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

Progression-free survival(PFS)

Key secondary outcomes

Response rate (RR), Overall survival (OS), 1yr-survival rate, adverse effects, QOL assessment


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

gemcitabine monotherapy (1000mg/m2, Day1,8,15, every four week)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Histologically or cytologically confirmed non-small cell lung cancer
2) Stage III / IV or recurrence after surgery, without any indications for radiotherapy or surgery
3) Evaluable disease
4) Progressive disease or recurrence after one or more platinum-based regimens, two or more regimens containing cytotoxic drugs, docetaxel- or pemetrexed-containing regimen for non-squamaous cell carcinoma histology, and docetaxel-containing regimen for squamous cell carcinoma histology. Adjuvant platinum-based chemotherapy was considered as one regimen.
5) Pre-treated with EGFR-TKI in patients with active EGFR mutation.
6) Pre-treated with ALK inhibitor in ALK-positive patient
7) Interval; two week after thoracic radiotherapy
8) Age 20 year-old or over 20 year-old
9) ECOG Performance status 0-2
10) Adequate organ function, evaluated within 14 days before enrollment
11) Expected 12 weeks survival
12) Written informed consent

Key exclusion criteria

1) A history of gemcitabine treatment
2) Current or previous history of pulmonary fibrosis, interstitial pneumonitis or drug-induced pneumonia, revealed by chest X-ray film
3) Concurrent thoracic radiotherapy
4) A history of severe hypersensitivity against gemcitabine
5) Another active advanced malignancy that requires any concurrent treatment with treatment for lung cancer
6) Pleural effusion, ascites or peri-cardiac effusion requiring dranage.
7) Problematic complications
8) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy
9) Decision of ineligibility by a physician

Target sample size

21


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Seigo Minami

Organization

Osaka Police Hospital

Division name

Dept. of Respiratory Medicine

Zip code


Address

10-31 Kitayama-cho, Tennoji-ku, Osaka-city, Osaka 543-0035, Japan

TEL

06-6771-6051

Email

seigominami@oph.gr.jp


Public contact

Name of contact person

1st name
Middle name
Last name Seigo Minami

Organization

Osaka Police Hospital

Division name

Dept. of Respiratory Medicine

Zip code


Address

10-31 Kitayama-cho, Tennoji-ku, Osaka-city, Osaka 543-0035, Japan

TEL

06-6771-6051

Homepage URL


Email

seigominami@oph.gr.jp


Sponsor or person

Institute

Dept.Repiratory Medicine, Osaka Police Hospital

Institute

Department

Personal name



Funding Source

Organization

Dept.Repiratory Medicine, Osaka Police Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪警察病院(大阪府)


Other administrative information

Date of disclosure of the study information

2015 Year 06 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2015 Year 05 Month 02 Day

Date of IRB


Anticipated trial start date

2015 Year 06 Month 04 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2015 Year 06 Month 03 Day

Last modified on

2016 Year 08 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000020611


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name